secretoglobin family 1A member 1Genealiases: CC10 · CC16 · CCPBP · CCSP · UGB · UP-1
Q-omics provides the consensus-scored SCGB1A1 profile across patient tissues and cancer cell-line models. SCGB1A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SCGB1A1 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, SCGB1A1 RNA expression shows 11,692 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, LUAD, and LSCC as cancer lineages where SCGB1A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB1A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB1A1 survival associations across molecular data types. SCGB1A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB1A1 RNA expression–survival associations across cancer types. High SCGB1A1 expression shows unfavorable associations in COAD, KIRC, THCA, CHOL and KICH, but favorable associations in CESC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SCGB1A1 RNA expression.
This table summarizes SCGB1A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SCGB1A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB1A1 shows lower tumor expression in LUAD, LUSC, HNSC, BRCA and PRAD and higher tumor expression in LIHC. The LUAD box plot shows higher SCGB1A1 RNA expression in normal versus tumor tissue (log2 FC = −6.204, t-test p < 0.001).
This table shows molecular features associated with SCGB1A1 in patient tissues and cancer cell lines. In patient samples, SCGB1A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCGB1A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
